<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940535</url>
  </required_header>
  <id_info>
    <org_study_id>SW001</org_study_id>
    <nct_id>NCT02940535</nct_id>
  </id_info>
  <brief_title>Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response</brief_title>
  <official_title>Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navy General Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of the poor responder patients is very difficult. Currently, there is no any
      standard treatment for poor responder patients. The study is designed to test a modified
      GnRHa protocol for poor ovarian response, low dose GnRHa early luteal phase down regulation,
      compare with GnRHa ultra-short protocol. This is a randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live birth</measure>
    <time_frame>3 years</time_frame>
    <description>The event that a FETUS is born alive with heartbeats or RESPIRATION regardless of GESTATIONAL AGE. Such liveborn is called a newborn infant (INFANT, NEWBORN).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>3 years</time_frame>
    <description>Presence of fetal heart at transvaginal ultrasound at 6 weeks of gestation or 6 weeks after starting the intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>multiple pregnancy</measure>
    <time_frame>3 years</time_frame>
    <description>The condition of carrying two or more FETUSES.</description>
  </other_outcome>
  <other_outcome>
    <measure>miscarriage</measure>
    <time_frame>3 years</time_frame>
    <description>Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ectopic pregnancy</measure>
    <time_frame>3 years</time_frame>
    <description>A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (&gt;96%) occur in the FALLOPIAN TUBES, known as TUBAL PREGNANCY. They can be in other locations, such as UTERINE CERVIX; OVARY; and abdominal cavity (PREGNANCY, ABDOMINAL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose of HMG required</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of HMG stimulation</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of embryos obtained</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of embryos frozen</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 years</time_frame>
    <description>According to the Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE 2009). Some adverse events will be studied as separate outcomes, including ovarian hyperstimulation syndrome (OHSS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Congenital Abnormalities</measure>
    <time_frame>3 years</time_frame>
    <description>Malformations of organs or body parts during development in utero.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Subfertility, Female</condition>
  <condition>Ovulation Disorder</condition>
  <arm_group>
    <arm_group_label>Low Dose GnRHa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHa Ultra-short Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphereline (Triptorelin embonate)</intervention_name>
    <arm_group_label>Low Dose GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decapeptyl (Triptorelin)</intervention_name>
    <arm_group_label>GnRHa Ultra-short Protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human menopausal gonadotropin</intervention_name>
    <arm_group_label>Low Dose GnRHa</arm_group_label>
    <arm_group_label>GnRHa Ultra-short Protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <arm_group_label>Low Dose GnRHa</arm_group_label>
    <arm_group_label>GnRHa Ultra-short Protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least two of the following three features must be present: i. Advanced maternal age
             (≥40 years) or any other risk factor for POR (poor ovarian response); ii. A previous
             POR (≤3 oocytes with a conventional stimulation protocol); iii. An abnormal ovarian
             reserve test (i.e. AFC &lt;7 follicles or AMH &lt;1.1 ng/ml).

        Exclusion Criteria:

          -  Contraindications for IVF/ICSI

          -  Contraindications for pregnancy

          -  Primary ovarian insufficiency

          -  AFC &lt;3

          -  PGD/PGS
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Shang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunhai Chuai, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mingming Shu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming Zhou, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huiming Han, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mengnan Chen, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navy General Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Shang, Dr</last_name>
    <email>shang.wei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunhai Chuai, Dr</last_name>
      <phone>+86-18810892004</phone>
      <email>wangyh85@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Navy General Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Yunhai Chuai</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology, Navy General Hospital, Beijing</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

